Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15428757 | 0.83 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2APOLBCYP1A2 | |
| SCHEMBL404099 | 0.83 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2APOLBCYP1A2 | |
| SCHEMBL3869436 | 0.81 | KDM4E (0.43) | ALDH1A1MEN1KMT2APOLBCYP1A2 | |
| SCHEMBL11326122 | 0.80 | LMNA (0.53) | ALDH1A1MEN1KMT2APOLBCYP1A2 | |
| SCHEMBL1143383 | 0.80 | CYP1A2 (0.62) | ALDH1A1MEN1KMT2APOLBCYP1A2 | |
| SCHEMBL11443464 | 0.79 | MAPT (0.43) | ALDH1A1MEN1KMT2AMAPK1LMNA | |
| Hydrochloric Acid SCHEMBL11473767 | 0.79 | CYP1A2 (0.61) | ALDH1A1MEN1KMT2APOLBCYP1A2 | |
| SCHEMBL224624 | 0.76 | CYP1A2 (0.72) | ALDH1A1MEN1KMT2APOLBCYP1A2 | |
| SCHEMBL3860413 | 0.76 | RAB9A (0.68) | ALDH1A1MEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL15428582 | 0.75 | HSD17B10 (0.44) | ALDH1A1POLBCYP2C19MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112300157-B | Novel pyrazolopyridine compound with anti-tumor activity and preparation method thereof | 烟台大学 | 2021-08-20 | — | — | CN | disclosed |
| CN-112300157-A | Novel pyrazolopyridine compound with anti-tumor activity and preparation method thereof | 烟台大学 | 2021-02-02 | — | — | CN | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | ALDH1A1 260/4885MEN1 3449/4885KMT2A 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.